MA35615B1 - Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf - Google Patents
Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et rafInfo
- Publication number
- MA35615B1 MA35615B1 MA36908A MA36908A MA35615B1 MA 35615 B1 MA35615 B1 MA 35615B1 MA 36908 A MA36908 A MA 36908A MA 36908 A MA36908 A MA 36908A MA 35615 B1 MA35615 B1 MA 35615B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- raf
- cancer
- treatment
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des compositions contenant au moins un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf, et au moins un inhibiteur de pi3kb, ainsi que leurs utilisations en vue du traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306172A EP2570127A1 (fr) | 2011-09-16 | 2011-09-16 | Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF |
PCT/EP2012/068072 WO2013037943A1 (fr) | 2011-09-16 | 2012-09-14 | Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35615B1 true MA35615B1 (fr) | 2014-11-01 |
Family
ID=46851503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36908A MA35615B1 (fr) | 2011-09-16 | 2014-04-10 | Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf |
Country Status (25)
Country | Link |
---|---|
US (1) | US20140275078A1 (fr) |
EP (2) | EP2570127A1 (fr) |
JP (1) | JP2014530181A (fr) |
KR (1) | KR20140062143A (fr) |
CN (1) | CN103889418A (fr) |
AR (1) | AR087902A1 (fr) |
AU (1) | AU2012307309A1 (fr) |
BR (1) | BR112014005839A2 (fr) |
CA (1) | CA2847091A1 (fr) |
CL (1) | CL2014000606A1 (fr) |
CO (1) | CO6910192A2 (fr) |
CR (1) | CR20140102A (fr) |
DO (1) | DOP2014000046A (fr) |
EA (1) | EA201490638A1 (fr) |
EC (1) | ECSP14013244A (fr) |
GT (1) | GT201400038A (fr) |
IL (1) | IL231212A0 (fr) |
MA (1) | MA35615B1 (fr) |
MX (1) | MX2014003223A (fr) |
NI (1) | NI201400020A (fr) |
PE (1) | PE20141035A1 (fr) |
SG (1) | SG11201400380XA (fr) |
TN (1) | TN2014000086A1 (fr) |
UY (1) | UY34341A (fr) |
WO (1) | WO2013037943A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105209073A (zh) * | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
BR112015025101A2 (pt) * | 2013-04-05 | 2017-07-18 | Sanofi Sa | composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo |
WO2015051252A1 (fr) * | 2013-10-03 | 2015-04-09 | Duke University | Compositions et méthodes destinées à traiter les cancers ayant une activité jak2 |
WO2015161230A1 (fr) * | 2014-04-19 | 2015-10-22 | Massachusetts Institute Of Technology | Procédés de réduction de la résistance à un inhibiteur de kinase |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
KR101950094B1 (ko) | 2017-07-28 | 2019-02-19 | 이성재 | 보릿대 공예품 제작방법 |
CN113440616A (zh) * | 2020-03-25 | 2021-09-28 | 上海科州药物研发有限公司 | Ras或raf突变型癌症的联合疗法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2549159T3 (es) | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | Derivados de bencimidazol N3-alquilados como inhibidores de MEK |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
FR2951169B1 (fr) * | 2009-10-09 | 2011-12-02 | Sanofi Aventis | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
PT2448927E (pt) | 2009-07-02 | 2014-06-12 | Sanofi Sa | Novos derivados de (6-oxo-1,6-di-hidro-pirimidin-2-il)-amida, sua preparação e sua utilização farmacêutica como inibidores da fosforilação de akt |
-
2011
- 2011-09-16 EP EP11306172A patent/EP2570127A1/fr not_active Ceased
-
2012
- 2012-09-14 BR BR112014005839A patent/BR112014005839A2/pt not_active IP Right Cessation
- 2012-09-14 KR KR1020147009655A patent/KR20140062143A/ko not_active Application Discontinuation
- 2012-09-14 AU AU2012307309A patent/AU2012307309A1/en not_active Abandoned
- 2012-09-14 EA EA201490638A patent/EA201490638A1/ru unknown
- 2012-09-14 WO PCT/EP2012/068072 patent/WO2013037943A1/fr active Application Filing
- 2012-09-14 JP JP2014530237A patent/JP2014530181A/ja not_active Abandoned
- 2012-09-14 PE PE2014000346A patent/PE20141035A1/es not_active Application Discontinuation
- 2012-09-14 SG SG11201400380XA patent/SG11201400380XA/en unknown
- 2012-09-14 EP EP12759137.8A patent/EP2755653A1/fr not_active Withdrawn
- 2012-09-14 CA CA2847091A patent/CA2847091A1/fr not_active Abandoned
- 2012-09-14 MX MX2014003223A patent/MX2014003223A/es not_active Application Discontinuation
- 2012-09-14 US US14/343,935 patent/US20140275078A1/en not_active Abandoned
- 2012-09-14 CN CN201280051036.1A patent/CN103889418A/zh active Pending
- 2012-09-17 AR ARP120103421A patent/AR087902A1/es unknown
- 2012-09-17 UY UY0001034341A patent/UY34341A/es not_active Application Discontinuation
-
2014
- 2014-02-27 CR CR20140102A patent/CR20140102A/es unknown
- 2014-02-27 IL IL231212A patent/IL231212A0/en unknown
- 2014-02-28 TN TNP2014000086A patent/TN2014000086A1/en unknown
- 2014-03-03 GT GT201400038A patent/GT201400038A/es unknown
- 2014-03-04 DO DO2014000046A patent/DOP2014000046A/es unknown
- 2014-03-13 CL CL2014000606A patent/CL2014000606A1/es unknown
- 2014-03-14 CO CO14055689A patent/CO6910192A2/es unknown
- 2014-03-14 NI NI201400020A patent/NI201400020A/es unknown
- 2014-03-14 EC ECSP14013244 patent/ECSP14013244A/es unknown
- 2014-04-10 MA MA36908A patent/MA35615B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013037943A1 (fr) | 2013-03-21 |
EP2570127A1 (fr) | 2013-03-20 |
KR20140062143A (ko) | 2014-05-22 |
AU2012307309A1 (en) | 2014-04-03 |
CO6910192A2 (es) | 2014-03-31 |
US20140275078A1 (en) | 2014-09-18 |
CL2014000606A1 (es) | 2014-11-07 |
AR087902A1 (es) | 2014-04-23 |
PE20141035A1 (es) | 2014-09-04 |
CA2847091A1 (fr) | 2013-03-21 |
EP2755653A1 (fr) | 2014-07-23 |
MX2014003223A (es) | 2014-06-05 |
JP2014530181A (ja) | 2014-11-17 |
ECSP14013244A (es) | 2014-07-31 |
SG11201400380XA (en) | 2014-04-28 |
CR20140102A (es) | 2014-05-07 |
BR112014005839A2 (pt) | 2017-03-28 |
WO2013037943A8 (fr) | 2013-07-18 |
TN2014000086A1 (en) | 2015-07-01 |
CN103889418A (zh) | 2014-06-25 |
GT201400038A (es) | 2014-12-16 |
IL231212A0 (en) | 2014-04-30 |
DOP2014000046A (es) | 2014-07-15 |
NI201400020A (es) | 2014-04-23 |
EA201490638A1 (ru) | 2014-08-29 |
UY34341A (es) | 2013-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35615B1 (fr) | Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf | |
CR20130267A (es) | Inhibidores de nampt y rock | |
BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
EA201592223A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
UA118649C2 (uk) | ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR) | |
EA201592225A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
ECSP12012097A (es) | Derivados de fumarato de ácido graso y sus usos | |
NZ730134A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
GB201114051D0 (en) | Compounds and their uses | |
BR112013027500A2 (pt) | liberação controlada de imunossupressores de nanotransportadores sintéticos | |
BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
ECSP14030779A (es) | Inhibidores del nampt | |
MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
MA33045B1 (fr) | Composition pharmaceutique contenant de la linagliptine et facultativement un inhibiteur sglt-2, et ses utilisations | |
MX2013011177A (es) | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). | |
MX349886B (es) | Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. | |
BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
BR112015029462A8 (pt) | Inibidores de quinase | |
EA202091676A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
EA201400748A1 (ru) | Композиция для обработки семян | |
EA201690756A1 (ru) | Составы кускового моющего средства с улучшенным смягчающим действием на кожу, содержащие неионную полимерную структурирующую систему | |
CL2018001719A1 (es) | Tratamiento contra el mieloma múltiple (divisional solicitud 201600396) | |
FR2961402B1 (fr) | Compositions contenant des arabinoxylo-oligosaccharides et leurs utilisations | |
EA201500752A1 (ru) | Способ лечения заболеваний |